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In Brief
Arai et al. show that metalloprotease
Adam19 is essential for proper
differentiation of cardiac neural crest cells
(CNCCs) in murine embryogenesis.
Adam19 suppresses the response of
CNCCs to bone morphogenic protein by
cleaving its receptor Alk2, thus restricting
CNCC skeletogenic potential and
preventing cartilage formation in the
heart.
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In higher vertebrates, cephalic neural crest cells
(NCCs) form craniofacial skeleton by differentiating
into chondrocytes and osteoblasts. A subpopulation
of cephalic NCCs, cardiac NCCs (CNCCs), migrates
to the heart. However, CNCCs mostly do not yield
skeletogenic derivatives, and the molecular mecha-
nisms of this fate restriction remain elusive. We iden-
tify a disintegrin and metalloprotease 19 (Adam19) as
a position-specific fate regulator of NCCs. Adam19-
depleted mice abnormally form NCC-derived carti-
lage in their hearts through the upregulation of Sox9
levels in CNCCs. Moreover, NCC-lineage-specific
Sox9-overexpressing mice recapitulate CNCC chon-
drogenesis. In vitro experiments show that Adam19
mediates the cleavage of bone morphogenic protein
(BMP) type I receptor Alk2 (Acvr1), whereas pharma-
cogenetic approaches reveal that Adam19 inhibits
CNCC chondrogenesis by suppressing the BMP-
Sox9 cascade, presumably through processing
Alk2. These findings suggest a metalloprotease-
dependent mechanism attenuating cellular respon-
siveness to BMP ligands, which is essential for both
the positional restriction of NCC skeletogenesis and
normal heart development.
INTRODUCTION
Neural crest cells (NCCs) possess a unique ability to generate
morphologically and functionally different cell types, includingCell
This is an open access article undneurons, smooth muscle cells, melanocytes, and chondrocytes.
During vertebrate development, NCCs initially arise from the
dorsal neural tube as multipotent stem/progenitor cells and,
owing to their migratory properties, move readily within embry-
onic tissues (Le Douarin and Kalcheim, 1999). NCCs contribute
to the development of most organs in the body, which raises
an intriguing question of position-specific fate restriction inmulti-
potent NCCs during embryogenesis. The cephalic domain of the
neural crest yields NCCs differentiating into skeletogenic chon-
drocytes and osteoblasts only in the head and neck regions,
whereas in other body parts, bones and cartilages are of meso-
dermal origin (Dupin et al., 2018). It has been suggested that the
differential expression of Hox genes along the anteroposterior
axis limits the ability of NCC skeletogenesis (Le Douarin et al.,
2004). Thus, dermal bones are derived only from Hox NCCs,
whereas transfection with the Hox genes can abolish the skele-
togenic ability of cranial NCCs (Le Douarin et al., 2004; Abzhanov
et al., 2003; Creuzet et al., 2002). It is unclear, however, whether
there is a mechanism that limits the NCC skeletogenesis in the
heart located between the head and trunk regions.
Cardiac NCCs (CNCCs) are a subpopulation of cephalic NCCs
that migrate into the heart; they derive from a Hox+ region (rhom-
bomere levels 6–8) posterior to the area where Hox-dependent
regulations are observed (rhombomere level 4) (Etchevers
et al., 2001; Minoux et al., 2009). Transcription factor Ets1 or
extracellular matrix protein fibronectin 1 (Fn1) mutant mice
exhibit NCC-derived cartilage formation in their hearts (Chen
et al., 2015; Gao et al., 2010), implying that CNCCs have yet-un-
known programs restricting skeletogenesis other than Hox
genes. Abnormal cardiac chondrogenesis can be observed in
humans with heart disease of unexplained etiology, such as sud-
den infant death syndrome (Ferris and Aherne, 1971), suggesting
that certain pathological conditions in the heart may be related toReports 29, 603–616, October 15, 2019 ª 2019 The Author(s). 603
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the deficiency in the mechanisms limiting CNCC skeletogenic
differentiation.
CNCCs play a crucial role in heart development, including re-
modeling of pharyngeal arches, aorticopulmonary septation,
and valvulogenesis. Consequently, defects in CNCC differentia-
tion are associated with human cardiocraniofacial diseases such
as DiGeorge, velocardiofacial, and coloboma, heart defects,
atresia choanae, growth retardation, genital abnormalities, and
ear abnormalities (CHARGE) syndromes (Kirby et al., 1983;
Keyte and Hutson 2012). Therefore, understanding fundamental
molecular pathways controlling CNCC differentiation is impor-
tant for lowering the risk of congenital heart defects. However,
mechanisms controlling CNCC fate in the aorticopulmonary
(AP) septum are unknown.
A transmembrane protein, Adam19 (a disintegrin and metallo-
protease), is suggested as one of the candidate regulatory fac-
tors in CNCC fate determination, because Adam19 knockout
mice show membranous ventricular septal defects similar to
those caused by Ets1 or Fn1 defects (Chen et al., 2015; Gao
et al., 2010; Kurohara et al., 2004; Zhou et al., 2004). Moreover,
Adam19 expression in NCCs is required for the formation of the
ventricular septum and valves in the heart (Komatsu et al., 2007).
Despite these facts, the physiological and molecular mecha-
nisms underlying the contribution of Adam19 to heart develop-
ment are poorly understood.
ADAMproteasesmediate ectodomain shedding of transmem-
brane proteins such as membrane-anchored growth factors and
play crucial roles in development (Weber and Saftig, 2012).
Adam19 has a proteolytic-active extracellular domain (Chesneau
et al., 2003; Shirakabe et al., 2001) and has been reported to
participate in the proteolytic processing of cadherin-6B in chick
premigratory cranial NCCs (Schiffmacher et al., 2014); it can also
perform a nonproteolytic function by stabilizing Adam13, which
induces the expression of NCC markers in Xenopus (Li et al.,
2018). However, the substrate of Adam19 in mammalian heart
development has not been identified.
In this study, we explored the molecular characteristics of
CNCCs related to their phenotypic commitment in the heart
and identified Adam19 as a positional gatekeeper that is critical
for defining appropriate CNCC fate in development. Inmice lack-
ing Adam19, CNCCs differentiated into chondrocytes and
formed abnormal cartilage in the heart through the upregulation
of Sox9 levels. Adam19 mediated the ectodomain shedding of
bone morphogenic protein (BMP) receptor Alk2 and inhibited
the BMP-Sox9 cascade in the heart. Our study presents a cell-
autonomous mechanism of CNCC fate limitation based on
Adam19-mediated suppression of BMP signaling in the devel-
oping heart.
RESULTS
Preferential Expression of Adam19 in Cardiac NCCs and
Abnormal Cartilage Formation in Adam19/ Hearts
To visualize NCC-lineage cells in the mouse, we crossed
Wnt1-Cre mice with Rosa26CAG-LSL-tdTomato/+ (R26tdT) mice and
obtained the Wnt1-Cre;R26tdT mouse line (Danielian et al., 1998;
Madisen et al., 2010), in which NCCs were genetically labeled
by a fluorescent protein tdTomato (tdT). To measure Adam19604 Cell Reports 29, 603–616, October 15, 2019mRNA levels in postmigratory CNCCs, we performed qPCR on
tdT+ NCC populations that were isolated from dissected parts of
Wnt1-Cre;R26tdT mouse embryos (Figure 1A, tpo panel) using
fluorescence-activated cell sorting (FACS). The results showed
that CNCCs exhibited significantly higher Adam19 expression
comparedwith cranial and trunk NCCpopulations and non-neural
crest-derived heart cells at embryonic day (E) 13.5 (Figure 1A, bot-
tom panel). After migration, CNCCs were condensed in the AP
septum and were surrounded by myosin heavy chain 1+ (Myh1+)
myocardium (Figure 1B). To assess the pattern of Adam19-ex-
pressing cells, we generated Adam19Venus/+ knockin mice by in-
serting the Venus gene encoding an improved-type GFP deriva-
tive into the Adam19 genomic locus (Figures S1A–S1C).
Consistent with qPCR results, Adam19-Venus fluorescence was
preferentially observed in the heart of Adam19Venus/+ mice at
E13.5 (Figures S1D and S1E). Similar to the localization pattern
of tdT+ CNCCs in Wnt1-Cre;R26tdT mouse hearts (Figure 1B),
Adam19-Venus was detected in the aorta and pulmonary trunk
at E13.5 (Figure 1C), in the developing AP septum around
E12.5–E16.5, and in cardiac endothelial cells during all of the
analyzed embryonic stages (E10.5–E18.5), but was hardly seen
around aortic arch arteries where migrating CNCCs were already
located at E10.5 (Figure S2A). These results revealed that postmi-
gratory CNCCs in the AP septum expressed Adam19.
In the postmigratory CNCCs, Adam19 protein was detected
near the cell surface (Figure S2B, yellow arrowheads) and around
the cell nuclei (Figure S2B, white arrowheads), which is
consistent with the location of the Golgi apparatus (Yokozeki
et al., 2007).
Analysis of Alcian blue-stained whole-mount embryonic
hearts revealed the formation of a nodule between the aorta
and pulmonary artery (the AP septum region) in perinatal
Adam19/ mice, which displayed cartilaginous structure
(Figure 1D). Although Alcian blue-stained nodules were also
observed in one wild-type (WT) heart (1/10) and some
Adam19+/ hearts (4/10), theywere found in all of theAdam19/
hearts (10/10), in which they were significantly larger than those
in WT or Adam19+/ embryos (Figure 1E) and were detectable
from E15.5 onward, but not at E14.5 (Figure S2C). Immunostain-
ing for Sox9, a transcription factor of the chondrogenic lineage,
and cartilage extracellular matrix proteins aggrecan (Acan) and
type II collagen (Col2) confirmed the presence of cartilage nod-
ules in Adam19/ hearts but not in WT hearts at E18.5 (Fig-
ure S2D). Thus, Adam19/ hearts developed histologically
and molecularly defined cartilages.
The Abnormal Cartilage Is Derived from CNCCs
Typically Differentiating into Tenocyte-like Cells
To investigate whether the ectopic cartilage in Adam19/
hearts had the CNCC origin, we performed genetic lineage
tracing analysis. Given that endocardial cushion mesenchyme
comprises two cell types derived from endothelial cells and
NCCs (Jiang et al., 2000; Kovacic et al., 2012), we crossed
Tie2-Cre (endothelial cell origin) (Kisanuki et al., 2001) or Wnt1-
Cre (neural crest cell origin) mice with R26tdT reporter mice to
visualize each cell lineage. As expected, in the cartilage of
Adam19/;Tie2-Cre;R26tdT hearts, there were no tdT+ cells,
whereas in the cartilage of Adam19/;Wnt1-Cre; R26tdT hearts,
Figure 1. Preferential Expression of Adam19 in Cardiac NCCs and Abnormal Cartilage Formation in Adam19/ Hearts
(A) Adam19 mRNA expression in FACS-sorted cell populations was assessed by qPCR (n = 3 embryos). The level of Adam19 mRNA in cranial NCCs was
defined as 1.
(B)Wnt1-Cre;R26tdT heart at E13.5. Overall view (left panel). A heart section labeled with tdT (NCC lineage) and immunostained for myosin heavy chain 1 (Myh1;
right panel).
(C) Adam19Venus/+ heart at E13.5. Overall view (left panel). A heart section immunostained for Venus (anti-GFP antibody) and Myh1 (right panel). Arrowheads
indicate the AP septum. See also Figures S1, S2A, and S2B.
(D) Hearts of WT and Adam19/mice at E18.5. Right lateral views of Alcian blue-stained hearts (left panels). High-magnification images of boxed areas (center
panels). Eosin- and Alcian blue-stained heart sections (right panels). The inset shows a magnified view of the cartilage. Asterisks indicate hyperplastic valves in
Adam19/ mice and arrows indicate ectopic cartilages. Ao, aorta; PA, pulmonary artery; RV, right ventricle.
(E) Sizes of cartilaginous nodules calculated as maximal Alcian blue+ areas in WT, Adam19+/, and Adam19/ hearts at E18.5 (n = 10 embryos). The data are
shown as means ± SEMs; *p < 0.05. See also Figures S2C and S2D.all of the cells were tdT+ and located at the center of the CNCC
cluster (Figure 2A), indicating that the abnormal cartilage was
derived from CNCCs. Similar but smaller CNCC clusters were
also observed in Adam19+/+;Wnt1-Cre;R26tdT hearts at the
same position as in Adam19/ hearts (Figure 2A). A three-
dimensional reconstruction of whole-mount immunostaining re-
vealed a bridge-like structure of CNCC clusters between the
aorta and pulmonary artery and showed the presence of Col2+
cartilage in Adam19/-CNCC but not in Adam19+/+-CNCCclusters (Figure 2B; Video S1). These observations raised a
question regarding the terminal differentiation characteristics
of CNCC clusters in WT mice.
CNCCs migrating into the heart separate the common
outflow tract into the aortic and pulmonary trunks, and some
of them differentiate into smooth muscle cells surrounding
the aorta and pulmonary arteries (Jiang et al., 2000; Waldo
et al., 1998). However, little is known about the fate of the
CNCC subpopulation that reaches the AP septum. CNCCsCell Reports 29, 603–616, October 15, 2019 605
Figure 2. Abnormal Cartilage in Adam19/ Hearts Is Formed by CNCCs Typically Differentiating into Tenocyte-like Cells
(A) DAPI- and Alcian blue-stained heart sections at E18.5 (left panels) with magnified images of the boxed areas (center and right panels).
(B) Schematic representation of the heart; the observed area is indicated by a red box (left). Three-dimensional reconstruction of whole-mount hearts immu-
nostained for Col2 showing the absence (Adam19+/+; open arrowhead) or presence (Adam19/; closed arrowhead) of Col2+ structures (right panels). Arrows
indicate the connection between the aorta and pulmonary artery. Ao, aorta; PA, pulmonary artery; RA, right atrium; RV, right ventricle. See also Video S1.
(C) Sections of Adam19+/+;Scx-GFP and Adam19/;Scx-GFP hearts (E18.5) immunostained for Col1a1 and Scx-GFP. Arrowheads indicate Scx+ CNCCs.
(D) Three-dimensional reconstruction of whole-mount hearts immunostained for Col1a1. See also Video S2.
(E) Sections immunostained for smooth muscle cell marker Sm22a. Open arrowheads indicate Sm22a CNCC clusters.in the AP septum are adjacent to semilunar valves (Waldo
et al., 1998); therefore, we hypothesized that CNCC clusters
had the same characteristics as cardiac valvular cells, which
are similar in their genetic profile to tenocytes or ligament cells
and express transcription factor scleraxis (Scx) and extracel-
lular matrix protein type I collagen (Col1a1) (Levay et al.,
2008; Murchison et al., 2007). To examine the expression of
tenogenic marker Scx in CNCCs of the AP septum, we used
Scx-GFP transgenic mice (Sugimoto et al., 2013a). Analysis
of Scx-GFP;Wnt1-Cre;R26tdT hearts at E18.5 revealed that
CNCCs in the clusters expressed tenocyte markers Scx606 Cell Reports 29, 603–616, October 15, 2019(Murchison et al., 2007) and Col1a1 (Figures 2C and 2D; Video
S2) but not the smooth muscle cell marker Sm22a (Figure 2E),
indicating that WT CNCCs in the AP septum differentiated into
the tenogenic lineage.
Adam19 Expression in CNCCs Is Required for Their
Proper Cell Fate Decision
To determine which Adam19-expressing cell types were
required for proper CNCC differentiation, we generated mice
with a conditional Adam19-knockout allele (Adam19fl/fl) by
flippase-based recombination of the Adam19Venus knockin
Figure 3. Adam19 Expression in CNCCs Is Required for Their Proper Cell Fate Decision
(A–C) Images of Adam19fl/fl;R26tdT (A), Tie2-Cre;Adam19fl/fl;R26tdT (B), and Wnt1-Cre;Adam19fl/fl;R26tdT (C) hearts at E18.5. Eosin and Alcian blue staining
(left panels); a black arrow indicates the ectopic cartilage. Alcian blue-stained sections immunostained for chondrocyte and tenocytemarkers (right panels); white
arrows indicate Col1a1+ tenocyte-like cells and arrowheads indicate ectopic cartilages.
(D) Quantification of cartilage sizes in Adam19fl/fl;R26tdT, Tie2-Cre;Adam19fl/fl;R26tdT, and Wnt1-Cre;Adam19fl/fl;R26tdT hearts at E18.5. The numbers of hearts
with ectopic cartilage per that of analyzed hearts (n = 10 per genotype) are shown. The data are presented as means ± SEMs; *p < 0.05.
See also Figure S3.allele (Figures S1A and S1C). Adam19 was expressed both in
endothelial cells and CNCCs during heart development (Fig-
ures 1A and S2A); therefore, we bred Tie2-Cre or Wnt1-Cre
mice with Adam19fl/fl and R26tdT reporter mice (Adam19fl/fl;
R26tdT). None of the Adam19fl/fl;R26tdT embryos (0/10) and
only one of the Tie2-Cre;Adam19fl/fl;R26tdT embryos (1/10)
showed Alcian blue-stained nodules, and their cells in the
AP septum were positive for the tenocyte marker Col1a1 at
E18.5 (Figures 3A and 3B, arrows). In contrast, the majority
of Wnt1-Cre;Adam19fl/fl;R26tdT mice (9/10) developed ectopic
cardiac cartilages, which also were significantly larger than
those of the other genotypes (Figures 3C and 3D). Immuno-
staining of Wnt1-Cre;Adam19fl/fl;R26tdT hearts revealed
NCC-derived cartilages, which were surrounded by Col1a1+
tenocyte-like cells, indicating that these mice recapitulated
the cartilage phenotype of Adam19-constitutive knockout
mice (Figures 2 and 3C). These results suggest that Adam19
expression in CNCCs is required for the inhibition of the chon-
drogenic program in a cell-autonomous manner.
Defects in NCC patterning led to the homeotic transformation
of original skeletal parts (Minoux and Rijli, 2010). However,
Adam19/ embryos had no gross abnormality in skeletal
patterning at E18.5 (Figures S3A–S3C), and there was no signif-
icant difference in the distribution of Adam19+/+ and Adam19/
CNCCs (Figures S3D–S3F), indicating that Adam19 is involved in
the local cell fate specification of CNCCs rather than in NCC
patterning or migration.Adam19-Deficient CNCCs Exhibit Sox9 Upregulation
Before Abnormal Cartilage Formation
To elucidate the molecular mechanisms underlying the cartilage
phenotype of Adam19/ mice, we performed gene expression
profiling of CNCCs. Given that Adam19 was strongly expressed
in the hearts of WT mice at E13.5 (Figures 1A and 1C) and that
cardiac cartilage appeared in Adam19/ mice at E15.5 (Fig-
ure S2C), we analyzed gene expression in CNCCs from
Adam19+/+;Wnt1-Cre;R26tdT and Adam19/;Wnt1-Cre;R26tdT
hearts at E14.5. Although transcriptional profiles were, overall,
similar between the two genotypes, Adam19/ CNCCs ex-
hibited notable upregulation of Sox9 transcripts compared with
Adam19+/+ CNCCs by the weighted average difference (WAD)
method (Kadota et al., 2008; Figure 4A; Table S1), suggesting
that Adam19 negatively regulates Sox9 expression in CNCCs.
Sox9 and Scx are key transcription factors that regulate chon-
drocyte and tenocyte differentiation, respectively (Akiyama et al.,
2002; Mori-Akiyama et al., 2003; Murchison et al., 2007). Com-
mon precursor cells are both Sox9+ and Scx+ and form the junc-
tion between cartilage and a tendon/ligament (Sugimoto et al.,
2013b). Immunohistochemical analysis showed that at E14.5,
most Adam19+/+ and Adam19/ CNCCs in the AP septum ex-
pressed both Scx and Sox9 (Figure 4B), indicating that these
CNCCs included Scx+Sox9+ progenitors with both tenogenic
and chondrogenic features. However, Sox9 protein expression
was slightly higher in Adam19/ than in Adam19+/+ CNCCs,
which was consistent with the microarray data (Figures 4A andCell Reports 29, 603–616, October 15, 2019 607
Figure 4. Sox9 Upregulation in Adam19-Deficient CNCCs Is Crucial for Abnormal Cardiac Cartilage Formation
(A) Scatterplot of microarray data for Adam19+/+ and Adam19/ CNCCs at E14.5; 100 most differentially expressed genes (orange dots) were identified by the
WAD method. See also Table S1.
(legend continued on next page)
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4B, arrowhead). In controlAdam19+/+mice, the number of Sox9+
CNCCs gradually decreased at E16.5–E18.5, whereas in
Adam19/ mice, their number increased and remained high at
the center of the CNCC cluster, where cartilage formation was
observed (Figure S4).
Sox9 is the earliest marker for chondrogenic progenitor cells
also expressed at the prechondrogenic condensation stage, a
pivotal step in chondrogenesis (Hall andMiyake, 2000). To inves-
tigate whether the appearance of cartilaginous nodules in
Adam19/ hearts was related to abnormal prechondrogenic
condensation, we examined the condensation of WT and
Adam19/ CNCCs. Staining with peanut agglutinin (PNA), a
marker for mesenchymal cell aggregation, revealed that both
WT and Adam19/ CNCC clusters exhibited cell condensation
at E14.5 (Figures S5A and S5B), suggesting that Adam19 defi-
ciency does not affect CNCC condensation.
To further dissect the role of Adam19 in CNCCs, we assessed
cell proliferation and apoptosis by Ki67 and TUNEL staining,
respectively. The results revealed that Adam19/ CNCCs ex-
hibited enhanced local proliferation and no significant changes
in apoptosis in the AP septum at E16.5 (Figures S5C–S5E), indi-
cating that the failure to suppressSox9 expression inAdam19/
mice could be related to abnormal differentiation and prolifera-
tion of NCC-derived Scx+Sox9+ progenitors.
Sox9 Expression Levels Are Crucial for Cardiac
Cartilage Formation
To test the hypothesis that ectopic cardiac cartilage production
in Adam19/ CNCCs was due to Sox9 upregulation, we inves-
tigated whether the reduction of Sox9 gene dosage in CNCCs
could rescue the cardiac cartilage phenotype in Adam19/
mice by introducing a conditional floxed Sox9 allele (Sox9fl/+)
(Kist et al., 2002). Although CNCCs of Adam19/;Wnt1-Cre;
Sox9fl/+;R26tdT mice migrated into the heart and formed CNCC
clusters at the AP septum similar to those of Adam19/;Wnt1-
Cre;R26tdT mice, abnormal cartilage formation and chondro-
genic features such as Col2 expression were completely abol-
ished in Adam19/ CNCCs with reduced Sox9 expression (Fig-
ures 4C and 4D), and their differentiation into Col1a1-expressing
tenocyte-like cells in the AP septum was recovered (Figure 4C).
The rescue of the ectopic cartilage phenotype in Adam19/
hearts by Sox9 downregulation in CNCCs indicates that the
abnormal Col2 expression and chondrogenic differentiation in
Adam19/ CNCCs were induced by high Sox9 expression
levels.(B) Heart sections were immunostained for GFP and Sox9. An arrowhead indica
(C) Absence of ectopic cartilage formation inAdam19/;Wnt1-Cre;Sox9fl/+;R26td
chondrocyte markers Sox9 and Col2 and tenocyte markers Col1a1 (nR 3 embryo
Adam19/ CNCCs with downregulated Sox9 expression lost chondrogenic
(closed arrowhead).
(D) Quantification of maximum cartilage sizes at E18.5. The numbers of embryos
(E) Ectopic cartilage formation in Wnt1-Cre;CAG-LSL-Sox9 hearts was assesse
Col1a1 (nR 3 embryos per panel). A black arrow indicates the ectopic cartilage; a
like cells and arrowheads indicate ectopic cartilage.
(F) Quantification of maximum cartilage sizes at E18.5. The numbers of embryos
(G) Quantification of the cell numbers in CNCC clusters per section at E18.5 (n =
The data are presented as means ± SEMs; *p < 0.05.
See also Figure S6.Conversely, we also investigated whether Sox9 overexpres-
sion in CNCCs could induce ectopic cardiac cartilage
formation using transgenic CAG-LoxP-Stop-LoxP-Sox9-IRES-
EGFP (CAG-LSL-Sox9) mice overexpressing Sox9 in a Cre-
dependent manner (Kim et al., 2011). Wnt1-Cre;CAG-LSL-
Sox9 mice exhibited the CNCC-derived cardiac cartilage with
elevated expression of chondrogenic markers Sox9 and Col2
at the same locations as in Adam19/ mice (Figures 4E and
4F), but had no gross abnormality in original skeletal elements
at E18.5 (Figure S6), indicating that Sox9 overexpression reca-
pitulated the cardiac cartilage phenotype of Adam19/ mice.
Thus, high Sox9 expression in CNCCs is necessary and suffi-
cient for ectopic Col2 expression and abnormal cartilage forma-
tion in the developing heart, suggesting that Adam19 inhibits
cardiac chondrogenesis via suppressing Sox9 expression.
To further investigate whether cell proliferation in Adam19/
CNCCs (Figures S5E) was influenced by Sox9 expression levels,
we counted the cell numbers in CNCC clusters of relevant mu-
tants. Reduced Sox9 expression levels in Adam19/ CNCCs
caused a significant decrease in the number of cells present in
theCNCC cluster, whereas Sox9 overexpression in NCC-lineage
cells significantly increased the cell number (Figure 4G), indi-
cating that the increased cell numbers in Adam19/ CNCC
clusters are at least partially due to Sox9 upregulation.
Alk2 Is a Candidate Substrate of Adam19 in Developing
CNCCs
BMP signaling is one of the major pathways regulating chondro-
genesis through Sox9 expression (Zeng et al., 2002), and our
microarray analysis showed that Adam19/ CNCCs exhibited
increased transcription of BMP-regulated genes such as
Hand1 (Bonilla-Claudio et al., 2012; Vincentz et al., 2016) and
Has2 (Ma et al., 2005; Figure 4A; Table S1). Therefore, we next
examined the activation of BMP signaling in CNCCs. BMP
ligand-receptor interaction increases the kinase activity of type
I receptors, leading to the phosphorylation of Smad1, Smad5,
and Smad9 and downstream transcriptional changes (Wang
et al., 2014), and we observed an increase in phospho-Smad+
cells among Adam19/ CNCCs at E14.5 (Figure 5A), indicating
enhanced BMP signaling.
Proteases of the ADAM family have been reported to partici-
pate in ectodomain shedding of transforming growth factor b
(TGF-b)/BMP receptors and inhibit their signaling cascades
(Hurst et al., 2017; Liu et al., 2009). These findings, together
with our results on the requirement of Adam19 in CNCCstes Sox9+ CNCCs in the Adam19/ heart. See also Figures S4 and S5.
T hearts was detected by eosin and Alcian blue staining and immunostaining for
s per panel). Insets show higher-magnification views of CNCC cluster regions.
features (open arrowheads) and recovered the original tenogenic feature
with abnormal cartilages per that of analyzed embryos (n = 10) are shown.
d by eosin and Alcian blue staining and immunostaining for Sox9, Col2, and
magnified view is shown in the inset. A white arrow indicates Col1a1+ tenocyte-
with abnormal cartilages per those of analyzed embryos (n = 10) are shown.
8 embryos per genotype).
Cell Reports 29, 603–616, October 15, 2019 609
Figure 5. Alk2 Is a Candidate Substrate of Adam19 in Developing CNCCs
(A) Heart sections were immunostained for phospho-Smad1/5/9 (n = 3 embryos per genotype). An arrowhead indicates increased Smad1/5/9 phosphorylation in
Adam19/ CNCCs.
(B) Schematic representation of the expression vectors. SP, signal peptide; 30/50 TR, piggyBac terminal repeats.
(C) HEK293T cells co-expressing HA-Alk2-Myc with Tet-on-Adam19 or Tet-on-Adam19 E347A were incubated or not with doxycycline (Dox) and protease
inhibitor BB94 and analyzed by western blotting with the indicated antibodies.
(D) Heart sections were immunostained for Alk2 (N-terminal region) and Sox9 (n = 3 embryos per genotype). Boxed areas are enlarged in the insets.
(E) HEK293T cells co-expressing Alk2-Myc with Tet-on-Adam19 or Tet-on-Adam19 E347A were incubated with or without Dox and BMP6 and analyzed by
western blotting with the indicated antibodies. Alk2 protein was abundant in Adam19/ CNCCs (arrowhead). CTF, C-terminal fragment; FL, full length; pro and
mature, proenzyme and mature forms of Adam19, respectively.
See also Figure S7.
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(Figures 3C and 3D) and the enhanced BMP signaling in
Adam19/ CNCCs (Figures 4A and 5A), suggest that Adam19
may act through the cleavage of BMP receptors, thus inhibiting
BMP signaling in CNCCs. To test this hypothesis, we co-ex-
pressed Adam19 with the C-terminally Myc-tagged BMP recep-
tors (Bmpr1a, Bmpr1b, Bmpr2, and Alk2) in HEK293T cells (Fig-
ure S7A, top panel). The short fragment indicative of receptor
cleavage was detected only in cells co-expressing Adam19
with Alk2 but not with other BMP receptors (Figure S7A, red
arrowhead); however, Alk2 was not cleaved in cells expressing
protease-inactive Adam19 E347A (Figure S7A, lane 8). These
observations were further confirmed using the Tet-on system,
which enabled the induction of Adam19 expression by doxycy-
cline (Dox) (Kim et al., 2016; Figure 5B). The short Alk2 fragment
was not detected in Dox control cells (Figure 5C, lanes 1 and 2)
or cells expressing Adam19 E347A (Figure 5C, lane 4) and ap-
peared only in those expressing Adam19 WT (Figure 5C, lane
3), but disappeared after treatment with metalloprotease inhibi-
tor BB94 (Figure 5C, lane 5). These findings indicated that
Adam19 selectively induced Alk2 ectodomain shedding in
HEK293T cells.
We next asked whether human (h)ADAM19 also has a func-
tion to mediate the ectodomain shedding of hALK2. HEK293T
cells co-expressing hALK2 and hADAM19 but not the hA-
DAM19 E346A mutant demonstrated the cleavage of hALK2,
which was inhibited by BB94 (Figure S7B), indicating that
Adam19-mediated Alk2 processing is conserved from mice to
humans.
Alk2 expression is required for CNCC migration to the car-
diac outflow tract, where it is detected at E11.5 (Kaartinen
et al., 2004), suggesting the presence of Alk2 in postmigratory
CNCCs. Immunohistochemistry analysis using an antibody
against the Alk2 N terminus revealed that Alk2 protein was
abundantly present at the Sox9+ region of the AP septum in
theAdam19/ hearts, but not inWT hearts at E14.5 (Figure 5D),
indicating the accumulation of uncleaved Alk2 protein in
Adam19/ hearts.
Adam19 Reduces the Responsiveness to BMP6 in Alk2-
Expressing Cells
We next examined the response to a BMP ligand in Alk2-ex-
pressing HEK293T cells with and without Adam19. Given that
Alk2 binds BMP6 and BMP7 (Lavery et al., 2008; Macı´as-Silva
et al., 1998; Saremba et al., 2008) and that Bmp6;Bmp7 dou-
ble-knockout mice have defects in outflow tract formation, valve
morphogenesis, and ventricular septum (Kim et al., 2001), similar
to those in Adam19 or Alk2 mutants (Kaartinen et al., 2004; Kur-
ohara et al., 2004; Thomas et al., 2012; Zhou et al., 2004), we
used BMP6 as an Alk2 ligand in heart development. BMP6
administration increased the level of phospho-Smad1/5/9 in
Alk2-Myc-expressing HEK293T cells (Figure 5E, lanes 3 and 4)
compared to untreated cells (Figure 5E, lanes 1 and 2), which
was attenuated by Adam19 induction, followed by Alk2 process-
ing (Figure 5E, lanes 5 and 6). However, Smad1/5/9 phosphory-
lation was not influenced by Adam19 E347A expression (Fig-
ure 5E, lanes 7 and 8). These data indicate that Adam19-
mediated Alk2 ectodomain shedding reduces cellular respon-
siveness to the BMP ligand in vitro.BMP Type I Receptor Inhibition Abolishes the Ectopic
Cartilage Phenotype in Adam19/ Hearts
A constitutively activating mutation in ALK2 causes fibrodys-
plasia ossificans progressiva (FOP) in humans, which mani-
fests by ectopic endochondral bone formation with increased
phosphorylation of Smad1/5/9 (Kaplan et al., 2012; Yu et al.,
2008), similar to the phenotype of Adam19/ hearts. As
CNCC migration to the outflow tract is disrupted in Alk2
knockout or conditional knockout mice (Kaartinen et al.,
2004), these models could not be applied to study CNCCs
in the AP septum. We, therefore, used LDN-193189, a selec-
tive inhibitor of BMP type I receptor, which can reduce hetero-
topic ossification in the FOP mouse model with constitutively
active Alk2 (Cuny et al., 2008; Yu et al., 2008). To investigate
whether aberrant Bmp-Alk2 signaling was a cause of the
ectopic cartilage formation in Adam19/ mice, we treated
mutant mice with LDN-193189 at E14.25–E16.25—in other
words, from the end of CNCC migration until the decrease
of Adam19 expression in the AP septum (Figures 6A and
S2A). Inhibition of BMP type I receptor in Adam19/;Wnt1-
Cre;R26tdT embryos rescued the ectopic cartilage phenotype
accompanying marked reductions in Sox9 and Col2 expres-
sion while recovering Col1a1 expression (Figures 6B and
6C), suggesting that aberrant Sox9 expression and cardiac
cartilage formation in Adam19/ CNCCs depended on BMP
signaling.
To confirm that the reduction of Sox9 levels by the BMP inhib-
itor was essential for eliminating the cardiac cartilage pheno-
type, we also administered LDN-193189 to Sox9-overexpress-
ing (Wnt1-CreCAG-LSL-Sox9) mice. Because NCCs of Wnt1-
CreCAG-LSL-Sox9 mice expressed exogenous Sox9 before
the start of LDN-193189 administration, we confirmed that
thesemice had no ectopic cartilage nodules in the hearts before
treatment (Figure 6D). In contrast to Adam19/ mice, all of the
Sox9-overexpressing mice displayed cartilaginous nodules in
the heart after LDN-193189 treatment (Figures 6C and 6E), indi-
cating that aberrant BMP signaling induced cardiac cartilage
formation in Adam19-deficient CNCCs by upregulating Sox9
expression.
DISCUSSION
This study reveals a mechanism suppressing the chondrogenic
fates of NCCs; a transmembrane metalloprotease Adam19 me-
diates the ectodomain shedding of BMP type I receptor Alk2 and
negatively regulates BMP signaling in CNCCs in a cell-autono-
mous manner, thereby preventing aberrant Sox9 expression
and subsequent ectopic cartilage formation in the developing
heart (Figure 7).
BMP signaling through Alk2 is required for CNCC migra-
tion and outflow tract formation during heart development
(Kaartinen et al., 2004). Our data suggest that Adam19
attenuates the response of CNCCs to BMP ligands (Figure 5),
which is critical for local specification of their fate after migra-
tion to the AP septum of the heart (Figure 6). In our model (Fig-
ure 7), CNCC fate is determined by the balance between
BMP-Alk2 signaling and Adam19-mediated proteolytic regula-
tion in a spatiotemporally specific manner. The formation ofCell Reports 29, 603–616, October 15, 2019 611
Figure 6. BMP Type I Receptor Inhibition Abolishes the Ectopic Cartilage Phenotype in Adam19/ Hearts
(A) Schedule of LDN-193189 administration.
(B) Eosin and Alcian blue staining; insets show high-magnification views of CNCC clusters; a black arrow indicates the target area without cartilage (left panels).
Alcian blue-stained heart sections were immunostained for chondrocyte and tenocyte markers (nR 3 embryos per panel); open arrowheads indicate cartilage
markers and a closed arrowhead indicates the tendinous CNCC cluster (right panels).
(C) Quantification of the maximum cartilage sizes in the hearts of DMSO- or LDN-193189-treated Adam19/;Wnt1-Cre;R26tdT and Wnt1-Cre;CAG-LSL-
Sox9;R26tdTmice at E18.5. The numbers of embryoswith abnormal cartilages per the total number of analyzed embryos (n = 8) are shown. The data are presented
as means ± SEMs; *p < 0.05.
(D) Eosin/Alcian blue staining of E14.5 Wnt1-Cre;CAG-LSL-Sox9 heart sections did not reveal any Alcian blue+ nodules before LDN-193189 administration
(n = 3 embryos).
(E) Eosin- and Alcian blue-stained heart sections of DMSO- or LDN-193189-treated Wnt1-Cre;CAG-LSL-Sox9;R26tdT mice at E18.5; insets show high-magni-
fication views of CNCC clusters (left panels). Alcian blue-stained heart sections were immunostained for chondrocyte and tenocyte markers (right panels; nR 3
embryos per panel).rudimentary cartilaginous nodules in control WT, Adam19+/,
and CAG-LSL-Sox9 hearts does not contradict this model
and implies that the role of Adam19-dependent regulation is
basically to minimize chondrogenic differentiation in CNCCs,
which was abrogated in most cases as a consequence of
Adam19-mediated proteolysis (Figures 1E, 4F, and 7).
Several proteins were shown to inhibit the skeletogenic dif-
ferentiation of NCCs in mice. Neural crest stem cell transcrip-
tion factor Sox10 negatively affected the mesenchymal fate
decision of NCCs (John et al., 2011), whereas the deficiency
of lysine N-methyltransferase Ezh2 provoked the massive
derepression of Hox genes and downregulated the skeleto-
genic genes Col2, Runx2, Osterix, and ALP, but not Sox9612 Cell Reports 29, 603–616, October 15, 2019in the first branchial arch containing skeletogenic NCCs
(Schwarz et al., 2014). Unlike derepressed Hox proteins,
Adam19 inhibits signaling along the BMP-Sox9 axis and re-
duces the expression of its downstream target gene Col2
(Bell et al., 1997), thereby suppressing the chondrogenic po-
tential of CNCCs (Figures 4, 5, and 6). At the same time, the
ectopic cartilage was observed in mice with Sox9-overex-
pressing NCCs only in the heart but not in other tissues, at
least during embryogenesis (Figures 4E, 4F, and S6), suggest-
ing that fate restriction through Sox9 downregulation is a car-
diac-specific mechanism; therefore, Adam19 is required in
CNCCs and is involved in a mechanism that is distinct from
that regulated by Hox proteins. Our data support the notion
Figure 7. Schematic Representation of the Adam19-Dependent Fate
Restriction Pathway in CNCCs
Postmigratory CNCCs clustering at the AP septum represent Scx+Sox9+ teno-
chondrogenic progenitors, in which Adam19 suppresses BMP signaling and
expression of its target Sox9 gene by proteolytic processing of BMP type I
receptor Alk2; as a result, CNCCs differentiate into Col1a1+ tenocyte-like cells.
In the absence of Adam19, BMP signaling and Sox9 expression in CNCCs are
not inhibited, resulting in CNCC differentiation into Col2+ chondrocytes and
ectopic cartilage formation in the heart.that the limitation of the NCC skeletogenic potential is
controlled by distinct molecular pathways that determine posi-
tion-specific NCC fate during embryogenesis.
Several mechanisms can be conceived about the limited
effects of Wnt1-Cre;CAG-LSL-Sox9. The first is that Sox9
protein levels are regulated by ubiquitin-proteasomal degra-
dation (Akiyama et al., 2005; Hattori et al., 2013). Also,
Sox9 can be stabilized by Snai2 (Luanpitpong et al., 2016).
Therefore, excessive Sox9 proteins in NCCs may be degraded
by the proteasome. The second is that in the posterior part
of NCCs, we did not observe the cell condensation, which is
a pivotal step in skeletal development (Hall and Miyake,
2000). Therefore, we could observe the ectopic cartilage for-
mation only in the heart. Third, the promotor activity of CAG-
LSL-Sox9 is not very high. The levels of Sox9 mRNA in
Sox9-Cre;CAG-LSL-Sox9 is 1.5 times higher than WT (Kim
et al., 2011).
A recent study in chickens showed that a defined set of
genes (Sox8, Tfap2b, and Ets1) encoding transcription factors
that activate a cranial-specific Sox10 enhancer could repro-
gram trunk NCCs to exhibit cranial neural crest identity
with a chondrogenic potential (Simoes-Costa and Bronner,
2016). In mice, Ets1 deficiency causes cardiac cartilage for-
mation by NCCs similar to that in Adam19/ mutants (Gao
et al., 2010; Figure 2A). In our study, Adam19 knockout
did not influence the expression of Hox, Sox10, Sox8, Tfap2b,
Ets1, and Fn1 in CNCCs at E14.5 (Figure 4A; Table S1); how-
ever, it is possible that Adam19 acts as a downstream effector
of early NCC-specific genes, such as Ets1. Since Sox4 and
Sox11 are required for the formation of the outflow tract and
they can regulate Adam19 expression in vitro and in vivo(Paul et al., 2014), Adam19 gene expression is considered to
be directly controlled by both Sox4 and Sox11 in the AP
septum region.
Our CNCCmicroarray analysis did not reveal any downregula-
tions of early NCC marker genes expressions (Figure 4A;
Table S1), and NCC distribution was not impaired in Adam19-
deficient mice (Figures S3D and S3E). It is possible that
Adam10 mainly cleaves Cad6, and the Adam19 function is
dispensable in premigratory NCCs in mice.
Our data showed that WT CNCCs in the AP septum display
characteristics of tenocyte-like cells expressing Scx and
Col1a1 (Figures 2C and 2D; Video S2), which raises an
intriguing question of whether these tenogenic cells are also
produced by other NCCs in different body parts. Further
studies are required to address this issue. Although the roles
of particular transcription factors, secreted signaling mole-
cules, and epigenetic modifications in controlling NCC fate
have been investigated (Simo˜es-Costa and Bronner, 2015;
Hu et al., 2014), our study suggests that the metallopro-
tease-mediated proteolytic control also participates in the reg-
ulatory mechanisms of NCC fate choice.
Defects in CNCCs lead to congenital heart abnormalities,
including ventricular septal defects and abnormal valvulogen-
esis (Hutson and Kirby, 2007; Keyte and Hutson, 2012), which
are commonly caused by the deficiency of BMP6/BMP7, Alk2,
Adam19, and Sox9 (Kaartinen et al., 2004; Kim et al., 2001;
Kurohara et al., 2004; Thomas et al., 2012; Zhou et al.,
2004; Akiyama et al., 2004). The hearts of Adam19/
mice displayed hyperplastic valves and exhibited Sox9
upregulation (Figure 1D, asterisks), whereas Alk2 deletion in
the cushion mesenchyme resulted in bicuspid aortic valve for-
mation and the downregulation of Sox9 expression in aortic
valves (Thomas et al., 2012; Wang et al., 2005). These patho-
logical conditions could be explained by the disruption of
regulated Sox9 expression and cell proliferation. Because
Adam19 is also expressed by non-neural crest-derived cells
in the heart (Figures 1A, S2A, and S2B) and ventricular septal
defects were observed in only 3/10 hearts of NCC-specific
Adam19 conditional knockout mice with mild hyperplastic
valve phenotypes (data not shown), the Adam19-expressing
non-neural crest-derived cells may also contribute to the for-
mation of ventricular septa and valves during heart
development.
In humans, cardiac cartilage formation is observed in heart
diseases (Ferris and Aherne, 1971; McConnell, 1970), and
hADAM19 is also expressed in the heart (Wei et al., 2001).
Therefore, our hADAM19 data imply that human hearts
possess ADAM19 function that prevents abnormal cardiac
chondrogenesis (Figure S7B). Because Adam19 selectively
mediates the processing of Alk2 and has inhibitory effects
on BMP signaling cascades (Figures 5E and S7A), hA-
DAM19-hALK2 results also raise the possibility that ADAM19
protein or ADAM19 activator administration can be a thera-
peutic strategy for human pediatric diseases associated with
the constitutive activation of ALK2 (Figure S7B; Han et al.,
2018). Thus, our findings yield insights into the mechanisms
regulating NCC fate, as well as the etiologic and therapeutic
implications of human diseases.Cell Reports 29, 603–616, October 15, 2019 613
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Chemicals, Peptides, and Recombinant Proteins
Alcian Blue 8GX MP Biomedicals Cat# 152624
Alizarin Red S Wako Cat# 011-01192
Fluorescein Labeled Peanut Agglutinin (PNA) Vector Lab Cat# FL-1071
Alexa Fluor 647 Phalloidin Thermo Fisher Scientific Cat# A22287
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LDN193189 Hydrochloride Sigma-Aldrich Cat# SML0559-25MG
FSC 22 Frozen Section Compound Clear Leica Cat# 3801480
TRIzol Reagent Thermo Fisher Scientific Cat# 15596026
Recombinant Human BMP-6 Protein Peprotech Cat# 120-06
Collagenase Type 2 Worthington Cat# LS004176
Lipofectamine 2000 Transfection Reagent Thermo Fisher Scientific Cat# 11668019
Doxycycline Hyclate LKT Labs Cat# D5897
Bortezomib LC laboratory Cat# B-1408
Batimastat (BB94) Med Chem express Cat# HY-13564
Critical Commercial Assays
Power SYBR Green PCR Master Mix Thermo Fisher Scientific Cat# 4368706
SuperScript VILO cDNA Synthesis Kit Thermo Fisher Scientific Cat# 11754050
RNeasy Plus Micro Kit QIAGEN Cat# 74034
ApopTag Plus In Situ Apoptosis Fluorescein
Detection Kit
Millipore Cat# S7111
Gateway BP Clonase II Enzyme mix Thermo Fisher Scientific Cat# 11789020
Gateway LR Clonase II Enzyme mix Thermo Fisher Scientific Cat# 11791020
ECL Prime Western Blotting Detection Reagent GE Healthcare Cat# RPN2232
Deposited Data
Microarray in Adam19+/+ and Adam19/ CNCCs This paper GEO: GSE99551
Experimental Models: Cell Lines
HEK293T ATCC Cat# CRL-11268
HK3i ES Cells (Kiyonari et al., 2010) N/A
Experimental Models: Organisms/Strains
Mouse: Adam19+/ (Kurohara et al., 2004) N/A
Mouse: Wnt1-Cre: H2afvTg(Wnt1-cre)11Rth (Danielian et al., 1998) MGI:2386570
Mouse: Tie2-Cre: B6.Cg-Tg(Tek-cre)1Ywa RIKEN BRC (Kisanuki et al., 2001) Cat # RBRC04495
Mouse: R26tdT: B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J The Jackson Laboratory
(Madisen et al., 2010)
Cat# 007914
Mouse: Scx-GFP (Sugimoto et al., 2013a) N/A
Mouse: Sox9fl/fl (Kist et al., 2002) N/A
Mouse: CAG-LSL-Sox9: B6.Cg-Tg(CAG-mRFP1,-SOX9,EGFP)
1Haak
RIKEN BRC (Kim et al., 2011) Cat # RBRC05654
Mouse: Adam19Venus/+ This paper N/A
Mouse: Adam19fl/fl This paper N/A
Recombinant DNA
pCMV3-C-Myc Negative Control Vector (C-terminal Myc-tagged) Sino Biological Inc. Cat# CV014
Mouse ALK-2/ACVR1 Gene ORF cDNA clone expression
plasmid, C-Myc tag
Sino Biological Inc. Cat# MG50297-CM
Mouse ALK-3 / BMPRIA ORF mammalian expression plasmid,
C-Myc tag
Sino Biological Inc. Cat# MG50078-CM
Mouse ALK-6 / BMPR1B Gene ORF cDNA clone expression
plasmid, C-Myc tag
Sino Biological Inc. Cat# MG50004-CM
Human ACVR1 cDNA ORF Clone C-Myc tag Sino Biological Inc. Cat# HG14875-CM
Human ADAM19 cDNA ORF Clone in Cloning Vector Sino Biological Inc. Cat# HG18760-U
pDONR221 Thermo Fisher Scientific Cat# 12536017
PB-TAC-ERP2 (Kim et al., 2016) Cat# 80478 (Addgene)/
Cat# RDB13246 (RIKEN BRC)
pCAG-PBase (Kim et al., 2016) Cat# RDB13241 (RIKEN BRC)
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Software and Algorithms
DP2-BSW software Olympus N/A
Volocity software PerkinElmer N/A
R statistical software (v3.1.2). R Foundation for
Statistical Computing
https://www.r-project.org/
LAS X software Leica N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Atsuko
Sehara-Fujisawa (sehara.atsuko.3m@kyoto-u.ac.jp). Mouse lines, plasmids, and other reagents generated in the study will be
available upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Generation of Adam19/ (Kurohara et al., 2004), Wnt1-Cre (Danielian et al., 1998), Tie2-Cre (Kisanuki et al., 2001),
Rosa26CAG-LSL-tdTomato/+ (R26tdT) (Madisen et al., 2010), Scx-GFP (Sugimoto et al., 2013a), Sox9fl/fl (Kist et al., 2002), and
CAG-LSL-Sox9-IRES-EGFP (Kim et al., 2011) mice was previously described. Adam19Venus/+ and Adam19fl/+ mouse lines
(Accession number CDB1228K: http://www2.clst.riken.jp/arg/mutant%20mice%20list.html) were established as follows. A
bacterial artificial clone construct containing the mouse Adam19 gene (ID: B6Ng01-116D03) was purchased from RIKEN
BRC. The linearized targeting vector was transferred by electroporation into HK3i (C57BL/6 strain) embryonic stem cells (Kiyo-
nari et al., 2010), and correctly targeted cell clones were identified by PCR and Southern blotting as described (http://www2.
clst.riken.jp/arg/methods.html). Germline transmission was confirmed by PCR. Adam19Venus/+ mice were bred with FLPeR
mice (R26fki) (Farley et al., 2003) to remove the SA-2A-Venus and PGK neo cassettes and to generate Adam19fl/+ mice.
Genotyping was performed by PCR using primers L1F 50-CTGTCAGGCTCAGATAAGAAAAAGTC-30 and F2R 50-TGAGCA
AGACTCTCACAGGTG-30 (Figures S1A and S1C). The noon of the day when the plug was detected was considered embryonic
day 0.5 (E0.5). All mice were maintained on the C57BL/6J genetic background and both genders were used. All animal housing,
breeding, and experiments were performed following the guidelines of Kyoto University and RIKEN Kobe Branch, and they
were approved by the Animal Research Committee of Kyoto University (Permit Number: 120170) and Institutional Animal
Care and Use Committee of RIKEN Kobe Branch (Permit Number: A2001-03-73), and all efforts were made to minimize animal
suffering.
Cells
HEK293T cells cultured in DMEM supplemented with 10% FBS (Moregate) were transfected with Tet-on-Adam19 or -Adam19-
E347A and pCAG-PBase (piggyBac transposase) at a molar ratio of 7:1 using Lipofectamine 2000 (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. Stably transfected clones were obtained by antibiotic selection with 100 mg/ml hygromycin B
(Wako) and 1 mg/ml puromycin (Sigma-Aldrich) and FACS sorting with anti-HA antibodies (Sigma-Aldrich, H3663; 1:400), anti-ALK-2
antibodies (R&D Systems, MAB637; 1:200) or anti-FLAG antibodies (Sigma-Aldrich, F1804; 1:400), and cells were analyzed in
different assays (Figures 5C, 5E, and S7). For the doxycycline induction assay, cells were incubated with or without 2 mg/ml doxy-
cycline (LKT Labs) for 24 h. For inhibition of Adam19 protease activity, cells were treated with 15 mM BB94 (Batimastat; MedChem
Express) at the same time as with doxycycline. To inhibit proteasomal degradation, cells were treated with 10 mM bortezomib
(LC Laboratory) for the last 6 h of the assay. In the BMP6 treatment experiment, cells were incubated with 2 mg/ml doxycycline
for 36 h and with 10 mM bortezomib for the last 12 h, and then with 100 ng/ml recombinant human BMP-6 (PeproTech) for 3 h.
Cultured cells were maintained at 37C and 5% CO2.
METHOD DETAILS
Cell Sorting
Mice at different stages of pregnancy were sacrificed by cervical dislocation and embryos were extracted. Isolated head, heart, and
trunk tissues were cut into small pieces and digested with 0.2% collagenase type 2 (Worthington) by gentle pipetting. Dissociated
cells were resuspended in DMEM (Thermo Fisher Scientific) supplemented with 2 mM EDTA and 5% heat-inactivated fetal bovine
serum (FBS; Moregate), and filtered through 35-mm cell strainer caps (BD Falcon). tdT+ cells were sorted using a FACSAria II cell
sorter (BD Biosciences) and considered CNCCs.Cell Reports 29, 603–616.e1–e5, October 15, 2019 e3
Quantitative PCR
FACS-sorted tdT+ or tdT- CNCCs were directly collected into TRIzol (Invitrogen) for total RNA extraction and cDNA was synthesized
using SuperScript VILO (Invitrogen) according to the manufacturer’s instructions. Quantitative PCR was performed in a Step One
Plus PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) and the following primers:
Adam19 forward 50-CTTCCAAGGCACCACCAT-30 and
reverse 50-TGGCATTCTCGGAGTGGT-30;
Rpl13a forward 50-GTGGTCCCTGCTGCTCTCAAG-30 and
reverse 50-CGATAGTGCATCTTGGCCTTTT-30.
The expression of the Adam19 gene was normalized to that of the ribosomal protein L13a-encoding gene (Rpl13a) used as a
control.
Microarray Analysis
To identify genes differentially expressed in Adam19+/+ and Adam19/ CNCCs, total RNA was extracted from sorted tdT+ CNCCs
using the RNeasy Plus Micro Kit (QIAGEN) and analyzed usingMouse Gene 1.0 ST Array (Affymetrix). The top 100 genes showing the
highest expression difference were evaluated with the WAD method using R software (Kadota et al., 2008).
Histology and Immunostaining
Embryonic and fetal hearts were isolated, fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) at 4C for 2–16 h, and
immersed in 30% sucrose in PBS. Fixed hearts were embedded in FSC22 compound (Leica), frozen in liquid nitrogen, and sectioned
at 10-mm thickness using a cryostat (Leica). The quality of the thawed samples was verified based on the expression of Venus or GFP
proteins detected by an anti-GFP antibody. Sections were washed thrice with PBS containing 0.1% Triton X-100 for 5 min and incu-
bated with blocking solution (Blocking One, Nacalai) for 1 h at room temperature. Immunostaining was performed using the following
primary antibodies: goat anti-GFP (Rockland, 600-101-215; 1:100), mouse anti-Myh1 (DSHB, MF20; 1:100), rat anti-CD31 (BD
PharMingen, 550274; 1:400), rabbit anti-Sox9 (Millipore, AB5535; 1:1000), rabbit anti-aggrecan (Millipore, AB1031; 1:400), rabbit
anti-Col1a1 (Bio-Rad, 2150-1410; 1:400), rabbit anti-Sm22a (Abcam, ab14106; 1:1000), rabbit anti-Col2 (Abcam, ab34712;
1:100), rabbit anti-phospho-Smad1/5/9 (Cell Signaling Technology, 13820; 1:100), and mouse anti-Alk2 (R&D systems, MAB637;
1:100). Signals were detected using secondary antibodies conjugated with Alexa488/594/647 (Molecular Probes; 1:500); nuclei
were counterstained with DAPI. For whole-mount immunostaining, samples were processed according to the iDISCO protocol
(https://www.idisco.info) (Renier et al., 2014) and cleared with CUBIC-1 reagent (Susaki et al., 2014). All images and movies were
acquired using a TCS-SP8 confocal microscope system and the LAS X software (Leica).
Quantification of Cell Apoptosis and Proliferation
The TUNEL assay was performed using the ApopTag Plus In Situ Apoptosis Fluorescein Detection Kit (Millipore, S7111) according
to the manufacturer’s instructions. Subsequently, sections were immunostained for Ki67 (Abcam, ab15580; 1:1,000) and counter-
stained with DAPI. The ratios of apoptotic to total nuclei and proliferative to total nuclei in CNCC clusters were quantified using
the Volocity software (PerkinElmer).
Cartilage Staining
For whole-mount heart staining, excised hearts were first fixed in 4% paraformaldehyde in PBS at 4C for 16 h and then in 95%
ethanol for 16 h and acetone for 16 h and stained with 0.03% alcian blue 8GX (MP Biomedicals) in 70% ethanol at 37C for
2 days. Hearts were incubated in 1% potassium hydroxide until complete discoloration, dehydrated in methanol series (50%,
75%, and 100%) in PBS for 20 min and cleared in benzyl benzoate:benzyl alcohol (2:1) for 1 h. Images were captured using an
M205C stereomicroscope (Leica). Cryosections were stained with 0.1% alcian blue 8GX in 3% acetic acid for 30 min at room
temperature, washed three times with 3% acetic acid and 0.1% Triton X-100 in PBS, and immunostained with antibodies. After
observation under a TCS-SP8 confocal microscope, sections were rinsed in 0.1% Triton X-100/PBS and counterstained with eosin.
Images were captured under a BX50 microscope (Olympus) equipped with a DP72 digital camera (Olympus) and the size of alcian
blue-positive cartilage was measured using the DP2-BSW software (Olympus).
Plasmids
Expression plasmids for mouse type I Bmp receptors (Bmpr1a/Bmpr1b/Alk2) and human ALK2 containing a C-terminal Myc tag were
purchased from Sino Biological Inc. Mouse Bmpr2 was subcloned into the pCMV3-C-Myc mammalian expression vector (Sino
Biological Inc). In some experiments (Figures 5C and S7), an HA or 3xFLAG tag was introduced directly after the signal sequence
in all Bmp receptor expression plasmids. The Tet-on vector used in this study was based on PB-TAC-ERP2 (Kim et al., 2016), where
the main expression cassettes were flanked by inverted piggyBac terminal repeats enabling their stable genome integration (Fig-
ure 5B). Human ADAM19 cDNA was purchased from Sino Biological Inc. Mouse Adam19 or human ADAM19 was subcloned into
the pDONR vector (Thermo Fisher Scientific) and then introduced into the PB-TAC-ERP2 Tet-on vector using the Gateway systeme4 Cell Reports 29, 603–616.e1–e5, October 15, 2019
(Thermo Fisher Scientific). Mutant mouse Adam19 and human ADAM19 genes encoding the EA substitution in the Adam19 catalytic
site were obtained by PCR as previously described (Chesneau et al., 2003) using the following primers:
mouse Adam19 E347A forward 50-GCGATTGGCCACAACTTTG-30 and reverse 50-ATGGGCCACAGTGGAGGCTA-30;
human ADAM19 E346A forward 50-GCGATGGGCCACAACTTT-30 and reverse 50-GTGGGCCATGGTGGCAG-30.
Western Blotting Analysis
HEK293T cells were lysed in RIPA buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-40, 0.1% sodium
deoxycholate) containing 1% protease inhibitor cocktail (Nacalai) with magnetic stirring at 4C for 1 h and subjected to SDS-PAGE.
Proteins were transferred onto PVDF membranes (Immobilon-P; Millipore) and probed with the following primary antibodies: mouse
anti-Myc tag (Cell Signaling Technology, 2276S, 9B11; 1:2,000), rabbit anti-Adam19 (generated in the Sehara lab; 1:2,000), mouse
anti-b-actin (Santa Cruz, sc-69879, clone AC-15; 1:2,000), mouse anti-HA (Sigma-Aldrich, H3663; 1:2,000), rabbit anti-phospho-
Smad1/5/9 (Cell Signaling Technology, 13820; 1:400), and anti-Smad1 (Cell Signaling Technology, 6944, D59D7; 1:2,000). After
washing, protein-primary antibody binding was detected with HRP-conjugated anti-mouse or anti-rabbit IgG (Cell Signaling
Technology; 1:5,000) and visualized by chemiluminescence (ECL Plus; GE Healthcare). Images were acquired with ImageQuant
LAS 4000 (GE Healthcare).
LDN-193189 Treatment
Mice were treated with LDN-193189, a BMP type I receptor inhibitor, as previously described (Yu et al., 2008) with minor modifica-
tions. Briefly, LDN-193189 (Sigma-Aldrich) was dissolved in 10% dimethyl sulfoxide (DMSO) in PBS and administered to pregnant
mice intraperitoneally (3 mg/kg every 12 h) at E14.25–E16.25; 10%DMSO in PBSwas administered to the control group. The treated
embryos were analyzed at E18.5 (Figure 6A).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were conducted using R statistical software (v3.1.2). The significance of the differences between two groups
was analyzed by Student’s t test and among more than two groups by one-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test. The LDN-193189 treatment data (Figure 6C) were analyzed using two-way ANOVA followed by Tukey’s post hoc test.
P-values less than 0.05 indicated statistical significance.
DATA AND CODE AVAILABILITY
The accession number for the array data reported in this paper is Gene Expression Omnibus: GSE99551.Cell Reports 29, 603–616.e1–e5, October 15, 2019 e5
